Leyden Laboratories describes new SARS-CoV-2 binding polypeptides

May 30, 2024

Leyden Laboratories BV has patented polypeptides acting as spike glycoprotein (S) (SARS-CoV-2; COVID-19 virus) ligands reported to be useful for the treatment of SARS-CoV-2 infections.

BioWorld Science Infection Coronavirus Patents

Today's news in brief

BioWorld

BioWorld briefs for April 3, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 3, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Impact of Trump tariffs on med tech proving difficult to anticipate

BioWorld MedTech

The Trump administration’s declaration of a new round of tariffs did not sit well with trade associations, but the impact of those tariffs may vary somewhat by...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...